Bioventus Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $94.29M TTM base FCF (operating cash flow $96.87M less capex $2.59M); 8% annual FCF growth years 1-5; 4% years 6-10; 9.5% discount rate; 3% terminal growth; $233.36M net debt ($263.75M total debt less $30.39M cash); 84.09M shares outstanding.

Reasoning: Bioventus is a profitable, growing orthobiologics and surgical-solutions medtech company with a recurring, capital-light cash-flow profile, making a standard unlevered FCF DCF the appropriate method; the growth and discount-rate assumptions reflect its recent double-digit cash-flow growth and moderate financial leverage.